Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 823 participants.
Also called NCT01874431
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 823 participants
- Sponsor
- Registry
-
NCT01874431 -
2012-004179-38
-
- Main results
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial
- Other papers using this trial's data
- Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
- Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Hong Kong SAR China, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, South Africa, South Korea, Spain, Sweden, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT01874431. Randomized; quadruple masking; primary purpose treatment. Start 2013-06-12 (actual); primary completion 2014-07-09 (actual). Results posted on 2021-05-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
- Acronym
- ARTS-DN
- Condition
- Diabetic Nephropathies
- Intervention (Drug)
- Finerenone (BAY94-8862)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct01874431- Content hash
f83b151c3dec387fd2c36c94bcf3caa7e4e8e15089f06969bfad688dbc6e3883